Systemic B-cell lymphoma with preceding myelin oligodendrocyte glycoprotein antibody-associated disease: a case report and literature review

伴有髓鞘少突胶质细胞糖蛋白抗体相关疾病的系统性B细胞淋巴瘤:病例报告及文献综述

阅读:7

Abstract

BACKGROUND: The co-occurrence of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and hematological malignancies is infrequently described. We report a rare case of histopathologically confirmed MOGAD complicated by pancytopenia following corticosteroid therapy, which ultimately unveiled a concurrent systemic B-cell lymphoma. CASE PRESENTATION: A 76-year-old female presented with bilateral lower limb weakness and numbness persisting for two months. She was initially diagnosed with acute myelitis at an external institution and treated with intravenous methylprednisolone (IVMP). A relapse occurred one month after corticosteroid cessation. Upon admission, magnetic resonance imaging (MRI) demonstrated an enlarging spinal cord lesion and extensive enhancement of the cauda equina nerve roots. A spinal cord biopsy revealed necrosis, chronic inflammatory infiltration, and demyelination, without definitive evidence of tumor cells or atypical lymphoid cells. Immunohistochemical staining revealed a loss of MOG expression, while neurofilament (NF) staining confirmed relative axonal integrity with only focal loss within the affected area. The diagnosis of MOGAD was confirmed via cell-based assays, which showed MOG-IgG positivity in both serum (1:32) and cerebrospinal fluid (1:1). However, the patient was refractory to further IVMP treatment and subsequently developed fever and pancytopenia. Peripheral blood immunophenotyping and bone marrow biopsy eventually established a diagnosis of systemic B-cell lymphoma. DISCUSSION: The coexistence of MOGAD and systemic B-cell lymphoma is rare. This case suggests that MOGAD may serve as a sentinel paraneoplastic manifestation of an underlying lymphoma.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。